inflammation and long-term outcomes in survivors of critical illness warrants further study (7).

As presented in Table E2 of our online supplement, the median (interquartile range) protein C activity (as a percent of control) in our study population was 80% (53–119%) on study Day 1, 88% (59–127%) on study Day 3, and 93% (64–137%) on study Day 5. Whereas the median levels of protein C activity in our cohort were higher than those reported in more homogeneous cohorts of patients with septic shock (8) or acute respiratory distress syndrome (9), a substantial number of participants in our study had mildly to moderately decreased protein C activity. Because lower levels of protein C activity are associated with greater mortality (10, 11), the relatively higher levels observed in our follow-up cohort may be attributable to the fact that our study included only those who survived at least 3 months following the index critical illness.

Finally, we also agree with Yasuma and colleagues that protein C is but one part of the complex coagulation cascade. Further study of the relationship between coagulation pathways and long-term outcomes in survivors of critical illness should be conducted. As with inflammation, evidence suggests that coagulation pathways can remain active after clinical resolution of acute illness and that higher levels of coagulation markers, such as D-dimer and thrombinantithrombin complexes, at hospital discharge are associated with greater 12-month mortality (12). Thus, the longitudinal study of relationships between markers of coagulation with long-term outcomes in survivors of critical illness should be conducted (7).

Author disclosures are available with the text of this letter at www.atsjournals.org.

Nathan E. Brummel, M.D., M.S.C.I. The Ohio State University Wexner Medical Center Columbus Ohio and Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center

Nashville, Tennessee

Lorraine B. Ware, M.D. Vanderbilt University Medical Center Nashville, Tennessee and

Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center Nashville, Tennessee

Timothy D. Girard, M.D., M.S.C.I.* University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania and Critical Illness Brain Dysfunction and Surviv

Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center Nashville, Tennessee

On behalf of all authors

ORCID IDs: 0000-0003-4308-0015 (N.E.B.); 0000-0002-9833-4871 (T.D.G.).

*Corresponding author (e-mail: timothy.girard@pitt.edu).

References

1. Brummel NE, Hughes CG, Thompson JL, Jackson JC, Pandharipande P, McNeil JB, et al. Inflammation and coagulation during critical illness and long-term cognitive impairment and disability. *Am J Respir Crit Care Med* 2021;203:699–706.

- Yende S, Kellum JA, Talisa VB, Peck Palmer OM, Chang CH, Filbin MR, et al. Long-term host immune response trajectories among hospitalized patients with sepsis. JAMA Netw Open 2019;2:e198686.
- Wichmann MA, Cruickshanks KJ, Carlsson CM, Chappell R, Fischer ME, Klein BE, et al. Long-term systemic inflammation and cognitive impairment in a population-based cohort. J Am Geriatr Soc 2014;62:1683–1691.
- Windham BG, Simpson BN, Lirette S, Bridges J, Bielak L, Peyser PA, et al. Associations between inflammation and cognitive function in African Americans and European Americans. J Am Geriatr Soc 2014;62:2303–2310.
- Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci 1997;52:M201–M208.
- Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999;47:639–646.
- Brummel NE. Long term outcomes of physical activity in older adults with critical illness. National Institutes of Health; 2016 [accessed May 5, 2021]. Available from: https://reporter.nih.gov/search/1vFutA6RBkqivB34YtjobA/ project-details/10130657.
- Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.
- Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/ acute respiratory distress syndrome. *Crit Care Med* 2007;35:1821–1828.
- Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. *Crit Care* 2006;10:R92.
- Brunkhorst F, Sakr Y, Hagel S, Reinhart K. Protein C concentrations correlate with organ dysfunction and predict outcome independent of the presence of sepsis. *Anesthesiology* 2007;107:15–23.
- Yende S, D'Angelo G, Mayr F, Kellum JA, Weissfeld L, Kaynar AM, et al.; GenIMS Investigators. Elevated hemostasis markers after pneumonia increases one-year risk of all-cause and cardiovascular deaths. *PLoS One* 2011;6:e22847.

Copyright © 2021 by the American Thoracic Society

Check for updates

Neighborhoods with 25% Minority Residents Are Still Mostly White

To the Editor:

We applaud Borker and colleagues for bringing attention to the important subject of racial health disparities in the care of patients with obstructive sleep apnea (OSA) (1). Given the impact of OSA on overall health, disparities in OSA care can have massive societal health implications. The structural racism embedded in the healthcare system and in American neighborhoods that the authors highlight in the discussion is unquestionably an impediment to the health of Black and

⁸ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern.

Originally Published in Press as DOI: 10.1164/rccm.202103-0810LE on June 16, 2021

CORRESPONDENCE

Hispanic Americans, and we appreciate the discussion of all these factors as they contribute to disparities.

Unfortunately, as designed, this study does not answer the question about racial health disparities in continuous positive airway pressure (CPAP) adherence; thus, we object to the authors' conclusion that "our findings extend results from earlier studies which have reported consistently that Black patients have lower CPAP usage than White patients." The authors go on to conclude that they have "observed racial and ethnic differences in adherence," but they have not done so with the reported data. Although their conclusions about the differences in the neighborhoods may be valid, this study does not address racial or ethnic differences in adherence and should not be interpreted as evidence that Black and Hispanic patients are less adherent to CPAP.

This study compares neighborhoods that are <1% Black or Hispanic with those that are >25% Black or Hispanic. In other words, it compares majority non-Hispanic White neighborhoods with other majority non-Hispanic White neighborhoods. Given that the populations in these "minority" neighborhoods could be up to 74% non-Hispanic White, any findings from this study are more likely to reflect differences in the behavior of non-Hispanic White people than they are Hispanic or Black people. Based on the data presented in this study, it is equally logical to conclude that non-Hispanic White people who live among higher concentrations of Black and/or Hispanic neighbors are less likely to adhere to CPAP. It is the authors' assumption of disadvantage and healthcare "mistrust" that leads them to assume it is the CPAP usage by the Black and Hispanic patients rather than by the White patients that accounts for their findings.

To learn about racial differences in CPAP adherence, we suggest including comparisons with neighborhoods that are at least 50% Black or Hispanic, preferably percentages that mirror the percentages of White people (e.g., comparing neighborhoods that are 99% White with those that are 99% Black). Otherwise, it is inappropriate to make conclusions about the behaviors of Black and Hispanic patients by comparing two populations in which they are significant minorities.

<u>Author disclosures</u> are available with the text of this letter at www.atsjournals.org.

Andrew R. Spector, M.D.* Duke University Medical Center Durham, North Carolina

Onyinye I. Iweala, M.D., Ph.D. University of North Carolina at Chapel Hill Chapel Hill, North Carolina

ORCID IDs: 0000-0003-4645-1205 (A.R.S.); 0000-0001-7470-7904 (O.I.I.).

*Corresponding author (e-mail: andrew.spector@duke.edu).

Reference

 Borker PV, Carmona E, Essien UR, Saeed GJ, Nouraie SM, Bakker JP, et al. Neighborhoods with greater prevalence of minority residents have lower CPAP adherence. Am J Respir Crit Care Med 2021;204: 339–346.

Copyright © 2021 by the American Thoracic Society

Check for updates

Reply to Spector and Iweala

From the Authors:

We thank Drs. Spector and Iweala for their interest in our recent report demonstrating lower continuous positive airway pressure (CPAP) adherence in communities with higher proportions of Black or Hispanic residents (1). Spector and Iweala argued that one cannot conclude from our analysis that Black and Hispanic people had lower CPAP adherence rates. We did not make this claim. Instead, we concluded that neighborhoods with greater *proportions* of Black or Hispanic residents have lower rates, a conclusion that Spector and Iweala acknowledge is supported by our data.

A further concern was raised that, in our quintile analysis, the highest quintile for minority prevalence was 25–100%, which, they argue, suggests that the vast majority of residents in such neighborhoods are white. In fact, the mean proportion of minority residents across the zip-code tabulation areas in this category was 48% in both the Black and Hispanic neighborhood analyses. Furthermore, our secondary analyses that modeled the proportion of Black and Hispanic residents as continuous variables led to very similar conclusions.

Spector and Iweala argued for a comparison of residents from communities that are 99% white with those that are 99% Black to assess whether racial disparities exist. Such an analysis would be unrepresentative of individual racial differences because most Black (and Hispanic) Americans do not live in such highly segregated neighborhoods.

Overall, Spector and Iweala appear singularly focused on individual-level differences, but we believe that such a focus limits the ability to fully understand how structural racism produces health disparities. Evidence suggests that discrimination at multiple levels contributes to many health disparities (2). A primary goal of our work was to investigate the association between neighborhood-level exposures and CPAP adherence, given evidence that differences in social and physical environments are important drivers of racial health disparities due to the legacy of residential segregation (3, 4). Our results support the contention that neighborhood-level factors contribute to disparities in CPAP adherence and highlight the importance of identifying and addressing community-level barriers—rather than solely focusing on the individual—to achieve health equity in sleep medicine (5).

<u>Author disclosures</u> are available with the text of this letter at www.atsjournals.org.

³ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern.

Supported by a grant from Philips Respironics, the American Thoracic Society Academic Sleep Pulmonary Integrated Research/Clinical Fellowship, and NIH grants HL127307 and HL082610. S.R.P. has received grant funding through his university from Bayer Pharmaceuticals, Philips Respironics, and Respicardia. S.M.N. has received grant funding through his university from Philips Respironics.

Originally Published in Press as DOI: 10.1164/rccm.202104-1030LE on June 2, 2021